These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
537 related items for PubMed ID: 8388188
21. No increase of calcitonin gene-related peptide in jugular blood during migraine. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. Ann Neurol; 2005 Oct; 58(4):561-8. PubMed ID: 16178016 [Abstract] [Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, Ferrari MD. Clin Pharmacol Ther; 1996 Oct; 60(4):452-60. PubMed ID: 8873693 [Abstract] [Full Text] [Related]
23. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Goadsby PJ, Edvinsson L. Headache; 1994 Oct; 34(7):394-9. PubMed ID: 7928323 [Abstract] [Full Text] [Related]
24. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, Michel MC. Pain; 2001 May; 92(1-2):101-6. PubMed ID: 11323131 [Abstract] [Full Text] [Related]
25. The mode of action of sumatriptan is vascular? A debate. Humphrey PP, Goadsby PJ. Cephalalgia; 1994 Dec; 14(6):401-10; discussion 393. PubMed ID: 7697699 [Abstract] [Full Text] [Related]
29. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Cephalalgia; 2005 Mar; 25(3):179-83. PubMed ID: 15689192 [Abstract] [Full Text] [Related]
30. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Headache; 2005 Mar; 45(7):850-61. PubMed ID: 15985101 [Abstract] [Full Text] [Related]
31. A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan. Ibrahimi K, Danser A, Terwindt GM, van den Meiracker AH, MaassenVanDenBrink A. Cephalalgia; 2017 Jan; 37(1):94-98. PubMed ID: 26951335 [Abstract] [Full Text] [Related]
35. Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs. Diener HC, Peters C, Rudzio M, Noe A, Dichgans J, Haux R, Ehrmann R, Tfelt-Hansen P. J Neurol; 1991 Aug; 238(5):245-50. PubMed ID: 1655985 [Abstract] [Full Text] [Related]
36. Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. den Boer MO, Villalón CM, Heiligers JP, Humphrey PP, Saxena PR. Br J Pharmacol; 1991 Feb; 102(2):323-30. PubMed ID: 1849764 [Abstract] [Full Text] [Related]